Rheumatology

Rheumatology

By ReachMDMedicine
Download on the App Store

All Rheumatology episodes

  • Keys to Maneuvering Discrepancies in Clinical Practice Guidelines
    Guest: Jason Busse, PhD

    Different clinical practice guidelines often have discrepancies from one another, making it a challenge for clinicians to determine which ones are more trustworthy. Here to break down the things clinicians should look for when sorting between guidelines that give discrepant recommendations is Dr. Jason Busse, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.

    5 min
  • Managing Osteoporosis: How to Create Personalized Treatment Plans
    Host: Michael Lewiecki, MD, FACP, FACE

    Although step therapy is the approach that many health plans and organizations are fond of, individualizing treatment decisions for patients with osteoporosis is essential, especially those who are at risk of fractures. To learn how you can create personalized treatment plans for patients with osteoporosis, tune in to hear Dr. Michael Lewiecki give us a recap of the session he presented at the 2024 Congress of Clinical Rheumatology.

    5 min
  • Center of the Target: Which Patients Are Most Likely to Develop Gout?
    Host: Richard Johnson, MD
    Guest: Abdul Abdellatif, MD, FASN

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • What’s New About Gout? Rheumatology Perspective
    Host: Richard Johnson, MD
    Guest: John K. Botson, MD, RPh

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • Treat or Refer: Who Is Responsible for Managing Gout?
    Host: John K. Botson, MD, RPh
    Guest: Abdul Abdellatif, MD, FASN

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • Gout Beyond the Joints: What’s the Hidden Danger?
    Host: Richard Johnson, MD

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    4 min
  • What Are the Emerging Therapies for Managing Gout?
    Host: Richard Johnson, MD
    Guest: John K. Botson, MD, RPh

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • What’s New About Gout? Nephrology Perspective
    Host: Abdul Abdellatif, MD, FASN
    Guest: Richard Johnson, MD

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • Can You Manage Patients With Uncontrolled Gout More Effectively?
    Host: Abdul Abdellatif, MD, FASN
    Guest: John K. Botson, MD, RPh

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min